

IN THE CLAIMS:

1.-11. (Cancelled)

12. (New) A composition for administration to a human subject suffering from a disorder in glutathione conjugation, which comprises:

a physiologically acceptable composition containing as an active ingredient at least one member capable of releasing elemental sulfur *in vivo* selected from the group consisting of elemental sulfur, salts of sulfur and acid salts of sulfur, and included in said composition at least one member selected from the group consisting of acids, oxoacid salts of sulfur and sulfate derivatives in a treatment effective quantity for administration to a human subject in need thereof for the treatment of a disorder in glutathione conjugation.

13. (New) The composition of claim 12, wherein the composition is in a formulation suitable for oral, parenteral, systemic or rectal administration.

14. (New) The composition of claim 12, wherein the composition is formulated as a medicine, a medicament, a food product or an artificial milk.

15. (New) The composition of claim 12, wherein the disorder in glutathione conjugation is heterozygous and homozygous glutathione transferase disorder or heterozygous and homozygous epoxide hydrolase disorder.

16. (New) The composition of claim 12, wherein the active ingredient is in a therapeutically effective dosage for human administration.

17. (New) A method of treating a glutathione conjugation disorder in a human subject caused by the accumulation of toxins in the liver, which comprises:

administering to a human subject suffering from a glutathione conjugation disorder a therapeutically effective quantity of a physiologically acceptable composition

containing as an active ingredient at least one member capable of releasing elemental sulfur *in vivo* selected from the group consisting of elemental sulfur, salts of sulfur and acid salts of sulfur, and included in said composition at least one member selected from the group consisting of acids, oxoacid salts of sulfur and sulfate derivatives whereby the sulfur released *in vivo* binds to the accumulated toxins in the liver and is released as elemental sulfur in the subject's bile.

18. (New) The method of claim 17, wherein the composition is in a formulation suitable for oral, parenteral, systemic or rectal administration.

19. (New) The method of claim 17, wherein the composition is formulated as a medicine, a medicament, a food product or an artificial milk.

20. (New) The method of claim 17, wherein the disorder in glutathione conjugation is heterozygous and homozygous glutathione transferase disorder or heterozygous and homozygous epoxide hydrolase disorder.

21. (New) The method of claim 17, wherein the active ingredient is present in a therapeutically effective dosage for human administration.